Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Saxagliptin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms MAPSS
- 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 24 Jan 2013 New trial record